The MTLE mouse a pharmacoresistant model of mesial temporal lobe epilepsy
The MTLE Mouse is a chemically induced model of mesial temporal lobe epilepsy.MESIAL TEMPORAL LOBE EPILEPSY (MTLE) is one of the most common form of partial epilepsy, characterized by the recurrence of paroxysmal discharges in temporal lobe structures, mainly within the hippocampus. It is associated with a unilateral hippocampal sclerosis, characterized by an extensive neuronal loss and a strong neuroplasticity in limbic structures, which appears to be triggered by an initial trauma during childhood.
Most patients with MTLE become resistant to antiepileptic drugs. Thereby, MTLE represents a major challenge in the clinical management of seizures.
A unilateral injection of a kainic acid in the dorsal hippocampus induces a status epilepticus, followed by a latent period of about three weeks. Hippocampal sclerosis and recurrent spontaneous hippocampal discharges, resistant to most classical AEDs, progressively develop and remain stable throughout the life of the animal. Altogether the MTLE Mouse reproduces behavioral, electroclinical and histological characteristics of human MTLE and represents a unique tool to qualify new AEDs that will relieve pharmacoresistant MTLE patients (Riban et al, 2002; Langlois et al, 2010).
RESISTANCE to classical AEDs
This model is resistant to AEDs classically used in clinical practice (valproate, carbamazepine and lamotrigine) within safety margins. Indeed, acute administration of those drugs remains ineffective in preventing spontaneous recurrent hippocampal discharges.
SENSITIVITY to new compounds
This model is sentitive to new AEDs (pregabalin, levetiracetam or NTP-2014) and allows you to assess the antiepileptic potential of your compound.
“NTP-2014 is a compound owned
and being developed by NeuroTherapeutics Pharma, Inc“